Business Wire

Workato Announces $110M at $1.7B Valuation to Transform How Enterprises Work with Integration-Led Automation

12.1.2021 16:00:00 EET | Business Wire | Press release

Share

Workato, the leader in integration-led automation, today announced $110 million in Series D funding led by global investment firm Altimeter Capital alongside Insight Partners. Pauline Yang, partner at Altimeter Capital, will join Workato's board of directors as an observer. Existing investors, Redpoint Ventures and Battery Ventures, also participated in the round. This investment brings the total capital raised by the company to over $221 million and values Workato at $1.7 billion.

“There’s been explosive growth in business apps and cloud technologies, but their potential remains largely untapped. This explosion has created tech chaos with siloed data, fragmented business processes and broken UX,” said Vijay Tella, CEO and co-founder of Workato. “Workato addresses this with a single platform built for business and IT that easily, reliably, and securely connects their apps, data, and business processes so teams can work smarter and faster. With our new investment, we’re looking forward to helping other companies around the world use integration-led automation to transform how they work."

Shaping the Future of Work for the Enterprise

Workato allows companies to maximize the value of their apps, data and people by making it easy to integrate disconnected data and applications, and securely automate workflows to accelerate business outcomes. Previously, businesses attempted to achieve this using a patchwork of different technologies, including Robotic Process Automation (RPA), Integration Platform as a Service (iPaaS), business process management (BPM) and chatbots. This legacy approach requires teams of specialists and results in fragile application and workflow connections that are insecure and hard to scale. Workato’s no code/low code platform combines enterprise-grade integration and automation capabilities in a single platform that is trusted by IT and easy to use for the business. With Workato, IT and business teams can more easily collaborate to rapidly integrate data, processes, applications and user experiences in almost any combination without compromising security and governance.

Workato’s integration-led automation platform is used by more than 7,000 businesses, including Broadcom, Coupa, Intuit, Autodesk, Nutanix and Rapid7. With a rapidly growing community of over 70,000 users who can create automations from scratch or get started faster with over 500,000 pre-built automation “recipes,” Workato’s cloud-native platform automates processes in marketing, sales, finance, HR, IT, and many other business areas so that teams can work faster and smarter.

A Record-Breaking Year Accelerated by COVID-19 and the Digital Imperative

Since raising its $70 million Series C round in late 2019, Workato has:

  • Nearly tripled its revenue and customer base
  • Increased workflows in production per customer threefold and workloads per customer fourfold across data integration, process automation, and chatbots
  • Seen the customer and partner community create over 500 connectors to new apps and systems each month
  • Ranked 96th in North America and 17th in the Bay Area in Deloitte’s 2020 Technology Fast 500
  • Named as a leader for the past three years in Gartner’s Magic Quadrant for Enterprise iPaaS, Workato is the only automation platform vendor that is also a leader in integration. Workato is also the only Automation vendor recognized in The Forrester Wave™: Strategic iPaaS and Hybrid Integration Platforms report, further underpinning Workato's integration-led approach to automation
  • Experienced 200% growth in new partners, and forged new technology partnerships with companies like Snowflake, Adobe, OutSystems, Workplace from Facebook and more

Workato will use the new investment to double down on its product innovation and technology development, continuing to lead the movement toward integration-led automation. The company will also expand its customer success program and launch its first user conference in 2021. Additionally, it will invest significantly in scaling teams in the U.S. and internationally in EMEA and APAC.

"The explosion of SaaS apps and increasingly complex hybrid environments have accelerated the need for integration-led automation. Workato has experienced such viral adoption because they are the first to combine enterprise-level integration and automation capabilities in a single platform with consumer ease of use,” said Pauline Yang, partner at Altimeter. "We are thrilled to be partnered with Vijay and the entire Workato team as they continue to transform how enterprises work."

“Our main challenges were the same challenges you see in most companies: rising costs, a growing IT backlog, and the need to effectively deal with risk. Now, two years into implementing Workato within our ML/NLP ecosystem, we’ve accelerated all of the work that IT does by over 30%. And although our company has grown rapidly, IT headcount and spend has remained flat,” said Wendy M. Pfeiffer, CIO at Nutanix. “Now that we’ve made headroom in our budget and within our existing team, we have the capacity for higher-level tasks. We’ve achieved 100% compliance with our SLAs, and our internal NPS scores regularly measure in the 90s. You can’t achieve this sustained performance by just staying the course. You have to use modern tools like Workato.”

About Workato

The leader in integration-led automation, Workato helps organizations work faster and smarter without compromising security and governance. Built for business and IT users, Workato is trusted by over 7,000 of the world's top brands like Broadcom, Intuit, Box, Autodesk, and HubSpot. Headquartered in Mountain View, Calif., Workato is backed by Altimeter Capital, Battery Ventures and Redpoint Ventures. For more information, visit www.workato.com or connect with us on social media:

1. Gartner. “Gartner Magic Quadrant for Enterprise Integration Platform as a Service.” Gartner., 2020, https://www.gartner.com/en/documents/3990698/magic-quadrant-for-enterprise-integration-platform-as-a-.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chanel Sedeno
Mission North for Workato
workato@missionnorth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye